Fig. 6: Proposed model of selective anticancer activity of NSLC01 in cancer cells with high NRF2 activation. | Cell Death & Disease

Fig. 6: Proposed model of selective anticancer activity of NSLC01 in cancer cells with high NRF2 activation.

From: Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway

Fig. 6

NSLC01 selectively activates eEF2K by inhibiting its phosphorylation at S366; activated eEF2K then phosphorylates the downstream eEF2 at T56, inhibiting its translation elongation function; this inhibition of translation reduces the availability of enzymes (ASNS, GHPDH, PSAT1, and PSPH) that drive the synthesis of asparagine and likely, serine as well necessary for cancer cell survival and proliferation.

Back to article page